晚期胃癌病人血清XRCC1基因多态性与奥沙利铂化疗效果的相关性

GENETIC POLYMORPHISM OF XRCC1 CORRELATED WITH THE OXALIPLATIN CHEMOTHERAPY FOR PATIENTS WITH ADVANCED GASTRIC CANCER

目的探讨XRCCIArg399Gln（G→A）基因多态性与晚期胃癌对以奥沙利铂为主的化疗敏感性的关系。方法晚期胃癌病人94例（Ⅲ期34例，Ⅳ期60例），应用以奥沙利铂为主的方案化疗，对60例Ⅳ期病人化疗2～3个周期后进行临床疗效评价，全部病人统计至疾病进展时间（TTP）。应用TaqMan—MGB探针等位基因分型技术进行基因分型。结果54．26％病人基因型为G／G，8．50％为A／A，37．24％为G／A。Ⅳ期60例病人化疗后临床获益率（CR＋PR＋SD）为70％，G／G、G／A＋A／A在化疗敏感组（CR＋PR＋SD）与不敏感组（PD）中的分布差异有显著性（χ2=6.747，P〈0．05；OR=4．680，95％CI=1．397～15．682，P=0．009）。94例病人中位TTP为9．0个月，G／O基因型为10．5个月，G／A＋A／A基因型为7．o个月，两者比较差异有显著性（χ2=7．113，P〈0．01）。结论XRCCI Arg399Gln基因多态性可能与晚期胃癌病人对奥沙利铂化疗的敏感性及生存时间相关。

Objective To study the correlation between genetic polymorphisms of XRCC1 Arg399Gln （G-A） and response to oxaliplatin-based chemotherapy in patients with advanced gastric cancer （AGC）. Methods Ninety four patients with AGC （34 with stage Ⅲ, and 60 with stage IV） were treated with oxaliplatin based chemotherapy. Clinical efficiency in 60 patients with stage 1V was assessed after 2 3 cycles of therapy, all the patients were followed until time to progress （TTP）. XRCC1 genotypes were detected by TaqMan MGB probe methods. Results 54.26% were G/G genotype, 8.50% were A/A genotype, and 37.24% were G/A genotype. The clinical benefit rate （CR＋PR＋SD） was 70G. Patients with G/G genotype showed distinct pre ponderance compared to those with G/A＋ A/A, between response group （CR ＋ PR ＋ SD） and non response group （SD） （χ2 = 6.747,P〈0. 05;OR=4.680,95G CI 1.397 15. 682,P=0. 009）. The median TTP of all patients was 9 months; G/Ggenotype was 10.5 months; G/A and A/A was 7.0 months. The significant differences between them were noticed （χ2=7. 113,P〈0.01）. Conclusion The XRCC1 Arg399Gln genetic polymorphisms may be associated with the clinical response to oxaliplatin-based chemotherapy and survival time in patients with advanced gastric cancer.